Advances in the use of carbapenem antibiotics in the management of serious bacterial infections in special patient populations. I: Safety and efficacy in children and elderly patients

Current Therapeutic Research - Clinical and Experimental

Volumn 61, Issue 5, 2000, Pages 289-320

  Okereke, Chukwuemeka S ^a,b  

^a UNIVERSITY OF RHODE ISLAND   (United States)

^b EISAI INC   (United States)

Author keywords

Bacterial infection; Carbapenem; Children; Elderly; Review; Treatment

Indexed keywords

CARBAPENEM; MEROPENEM;

ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; NEPHROTOXICITY; NEUROTOXICITY; PRIORITY JOURNAL; PSEUDOMONAS; TREATMENT INDICATION;

EID: 0034043246     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(00)80020-X     Document Type: Article

References (291)

1. 1. Yoshikawa TT. Infectious diseases, immunity and aging. Perspectives and prospects. In: Powers DC, Morley JE, Coe RM, eds. Aging, Immunity and Infection. New York: Springer Publishing; 1994:1-3.
2. 2. Crossley KB, Peterson PK. Infections in the elderly. Clin Infect Dis. 1996;22:209-215.
3. 3. United Nations. World Populations Prospects: The 1998 Revisions. New York: United Nations; WPP98. In press.
4. 4. Government Actuary's Department, Office for National Statistics. National Population Projections; 1996 Based. London: Stationary Office; 1999 (series PP3 No. 21).
5. 5. Gardner ID. The effect of aging on susceptibility to infection. Rev Infect Dis. 1980;2: 801-810.
6. 6. Schneider EL, Guralnik JM. The aging of America. Impact on health care costs. JAMA. 1990;263:2335-2340.
7. 7. Montauk SL. Home health care. Am Fam Phys. 1998;58:1608-1614.
8. 8. Leidl R, Stratmann D. Economic evaluation is essential in healthcare for the elderly. A viewpoint. Drugs Aging. 1998;13:255-262.
9. 9. Khaw K. How many, how old, how soon? Br Med J. 1999;319:1350-1352.
10. 10. Ebrahim S. Demographic shifts and medical training. Br Med J. 1999;319:1358-1360.
11. 11. Tonks A. Medicine must change to serve an ageing society. Br Med J. 1999;319:1450-1451. Editorial.
12. 12. Fox JP. Epidemiology of infectious diseases. In: Textbook of Pediatric Infectious Diseases. Feigin RD, Cherry JD, eds. 2nd ed. Philadelphia: WB Saunders; 1987:79-105.
13. 13. Keating MJ, Klimek JJ, Levine DS, et al. Effect of aging on the clinical significance of fever in ambulatory adult patients. J Am Geriatr Soc. 1984;32:282-287.
14. 14. Inagaki J, Rodriguez V, Bodey GP. Causes of death in cancer patients. Cancer. 1974; 33:568-573.
15. 15. Yoshikawa TT. Geriatric infectious diseases: An emerging problem. J Am Geriatr Soc. 1983,31:34-39.
16. 16. Carratala J, Roson B, Fernandez-Sevilla A, et al. Bacteremic pneumonia in neutropenic patients with cancer. Causes, empirical antibiotic therapy and outcome. Arch Intern Med. 1998;158:868-872.
17. 17. Farr BM. Prognosis and decisions in pneumonia. N Engl J Med. 1997;336:288-289.
18. 18. Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med. 1995;333: 1619-1624.
19. 19. Fagon JY, Chastre J, Hance AJ, et al. Nosocomial pneumonia in ventilated patients: A cohort study evaluating attributable mortality and hospital stay. Am J Med. 1993;94: 281-288.
20. 20. Yoshikawa TT. Treatment of nursing home-acquired pneumonia. J Am Geriatr Soc. 1991;39:1040-1041.
21. 21. Tzou-Yien L, Nelson JD, McCracken GH. Fever during treatment for bacterial meningitis. Pediatr Infect Dis J. 1984;4:319-322.
22. 22. Busca A, Saroglia EM, Giacchino M, et al. Analysis of early infectious complications in pediatric patients undergoing bone marrow transplantation. Supportive Care Cancer. 1999;7:253-259.
23. 23. Miranda-Novales MG, Belmont-Martinez L, Villasis-Keever MA, et al. Empirical antimicrobial therapy in pediatric patients with neutropenia and fever. Risk factors for treatment failure. Arch Med Res. 1998;29:331-335.
24. 24. Paganini H, Bologna R, Debbag R, et al. Fever and neutropenia in children with cancer in one pediatric hospital in Argentina. Pediatr Hematol Oncol. 1998;15:405-413.
25. 25. Hughes WT, Armstrong D, Bodey GP, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis. 1990;161:381-396.
26. 26. Yoshikawa TT, Norman DC. Treatment of infections in elderly patients. Med Clin North Am. 1995;79:651-661.
27. 27. Jones GR, Konsler GK, Dunaway RP, Puesk SN. Infection risk factors in febrile, neutropenic children and adolescents. Pediatr Hematol Oncol. 1996;13:217-219.
28. 28. Petrilli AS, Melaragno R, Barros KV, et al. Fever and neutropenia in children with cancer: A therapeutic approach related to the underlying disease. Pediatr Infect Dis J. 1993;12:916-921.
29. 29. Centers for Disease Control and US Department of Public Health and Human Services. National Nosocomial Infections Surveillance (NNIS) System Report, Data Summary from October 1986-April 1998. Washington, DC: US Department of Health and Human Services. 1998:1-25.
30. 30. Avila-Figueroa C, Cashat-Cruz M, Aranda-Patron E, et al. Prevalence of nosocomial infections in children: Survey of 21 hospitals in Mexico. Salud Publica Mex. 1999; 41(Suppl 1):S18-S25.
31. 31. Harbarth S, Ruef C, Francioli P, et al. Nosocomial infections in Swiss university hospitals: A multicentre survey and review of the published experience. Swiss-Nosso Network. Schweiz Med Wochenschr. 1999;129:1521-1528.
32. 32. Eveillard M, Pisante L, Mangeol A, et al. Specific features of nosocomial infections in the elderly at a general hospital center. 5 surveys of annual prevalence. Pathol Biol (Paris). 1998;46:741-749.
33. 33. Kollef MH, Sharpless L, Vlasnik J, et al. The impact of nosocomial infections on outcomes following cardiac surgery. Chest. 1997;112:666-675.
34. 34. Signorelli C, D'Alessandro D, Collina D, Fara GM. Prevalence survey of nosocomial infections in a pediatric hospital. J Hosp Infect. 1991;18:139-143.
35. 35. Nicholls TM, Morris AJ. Nosocomial infections in Auckland Healthcare hospitals. New Zealand Med J. 1997;110:314-316.
36. 36. Mantero E, Panizzo G, Tacchela A, et al. Occurrence of hospital infections in a department of pediatric heart surgery. Pediatr Med Chir. 1986;8:715-720.
37. 37. Tinoco JC, Salvador-Moysen J, Perez-Prado MC, et al. Epidemiology of nosocomial infections in a second level hospital. Salud Publica Mex. 1997;39:25-31.
38. 38. Pawa AK, Ramji S, Prakash K, Thirupuram S. Neonatal nosocomial infection: Profile and risk factors. Indian Pediatr. 1997;34:297-302.
39. 39. Greenway CA, Embil J, Orr PH, et al. Nosocomial pneumonia on general medical and surgical wards in a tertiary-care hospital. Infect Control Hosp Epidemiol. 1997;18:749-756.
40. 40. Legras A, Malvy D, Quinioux AI, et al. Nosocomial infections: Prospective survey of incidence in five French intensive care units. Intensive Care Med. 1998;24:1040-1046.
41. 41. Blumer JL. Carbapenems in pediatrics. Scand J Infect Dis. 1995;(Suppl 96):38-40.
42. 42. Levin AS, Barone AA, Penco J, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis. 1999;28:1008-1011.
43. 43. Perry PM, Markham A. Piperacillin/tazobactam. An updated review of its use in the treatment of bacterial infections. Drugs. 1999;57:805-843.
44. 44. Aswapokee N, Pruksachatvuthi S, Aswapokee P. Ciprofloxacin in severe infections. J Med Assoc Thailand. 1990;73:315-320.
45. 45. Rondelli R, Dionigi RV, Regazzi MB, et al. Ceftazidime in the treatment of Pseudomonas infections in intensive-care patients. Int J Clin Pharmacol Ther Toxicol. 1986;24:457-459.
46. 46. Cipro® [package insert]. New Haven, Connecticut: Bayer Corporation; 1998.
47. 47. Levaquin® [package insert]. Raritan, New Jersey: Ortho-McNeil Pharmaceutical; 1998.
48. 48. Edwards JR. Meropenem: A microbiological overview. J Antimicrob Chemother. 1995; 36(Suppl A):1-17.
49. 49. Scheckler WE, Peterson PJ. Nosocomial infections in 15 rural Wisconsin hospitals-results and conclusions from 6 months of comprehensive surveillance. Infect Control. 1986;7:397-402.
50. 50. Mulholland EK, Ogunlesi OO, Adegbola RA, et al. Etiology of serious infections in young Gambian infants. Pediatr Infect Dis J. 1999;18(10 Suppl):S35-S41.
51. 51. Landreau L, Moulaire V, Tarodo P, Jonquet O. Pneumococcal infections in intensive care. Retrospective 8 year study. Presse Med. 1999;28:1505-1508.
52. 52. Garcia-Garmendia JL, Ortiz-Leyba C, Garnacho-Montero J, et al. Mortality and the increase in length of stay attributable to the acquisition ofAcinetobacter in critically ill patients. Crit Care Med. 1999;27:1794-1799.
53. 53. Leelarasamee A, Dhiraputra C, Hunnangkul S. Severe pneumococcal infection at a Thai hospital. Int J Infect Dis. 1999;3:147-152.
54. 54. Baquero F, Loza E. Antibiotic resistance of microorganisms involved in ear, nose and throat infections. Pediatr Infect Dis J. 1994;13(Suppl 1):S9-S14.
55. 55. O'Hanley PD, Tam JY, Holodniy M. Infectious disorders. In: Melmon LK, Morrelli HF, Hoffman BB, Nierenberg DW, eds. Clinical Pharmacology. Basic Principles in Therapeutics. 3rd ed. New York: McGraw-Hill Inc; 1992:642-720.
56. 56. Sifuentes-Osornio J, Gonzalez R, Ponce-de-Leon A, Guerrero ML. Epidemiology and prognosis of Pseudomonas aeruginosa bacteremia in a tertiary care center. Rev Invest Clin. 1998;50:383-388.
57. 57. Cross AS. Evolving epidemiology of Pseudomonas aeruginosa infections. Eur J Clin Microbiol. 1985;4:156-159.
58. 58. Bergmans DC, Bonten MJ, van Tiel FH, et al. Cross-colonisation with Pseudomonas aeruginosa of patients in an intensive care unit. Thorax. 1998;53:1053-1058.
59. 59. Rastegar LA, Bahrami HH, Alaghehbandan R. Pseudomonas infections in Tohid Burn Center, Iran. Burns. 1998;24:637-641.
60. 60. Seigman-Igra Y, Ravona R, Primerman H, Giladi M. Pseudomonas aeruginosa bacteremia: An analysis of 123 episodes, with particular emphasis on the effect of antibiotic therapy. Int J Infect Dis. 1998;2:211-215.
61. 61. Harder E, Moller K, Skinhoj P. Enterobacteriaceae meningitis in adults: A review of 20 consecutive cases 1977-1997. Scand J Infect Dis. 1999;31:287-291.
62. 62. McClelland RS, Fowler VG, Sanders LL, et al. Staphylococcus aureus bacteremia among elderly vs young adult patients: Comparison of clinical features and mortality. Arch Intern Med. 1999;159:1244-1247.
63. 63. Madsen KM, Schonheydcr HC, Kristensen B, Sorensen HT. Secular trends in incidence and mortality of bacteremia in a Danish county 1981-1994. APMIS. 1999;107:346-352.
64. 64. Ismail NH, Lieu PK, Lien CT, Ling MT. Bacteremia in the elderly. Ann Acad Med Singapore. 1997;26:593-598.
65. 65. Ontero LO, Wey SB, Castelo A. Risk factors for mortality in Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol. 1998;19:32-37.
66. 66. Reilly A. Prevention and control of enterohaemorrhagic Escherichia coli (EHEC) infections: Memorandum from a WHO meeting. WHO consultation on prevention and control of enterohaemorrhagic Escherichia coli (EHEC) infections. Bull WHO. 1998;76:245-255.
67. 67. Barquet N, Domingo P, Cayla JA, et al. Meningococcal disease in a large urban population (Barcelona, 1987-1992): Predictors of dismal prognosis. Barcelona Meningococcal Disease Surveillance Group. Arch Intern Med. 1999;159:2329-2340.
68. 68. Marrie TJ. Pneumococcal pneumonia: Epidemiology and clinical features. Semin Respir Infect. 1999;14:227-236.
69. 69. Goel A, Bamford L, Hanslo D, Hussey G. Primary staphylococcal pneumonia in young children: A review of 100 cases. J Trop Pediatr. 1999;45:233-236.
70. 70. Jang TN, Kuo BI, Shen SH, et al. Nosocomial gram-negative bacteremia in critically ill patients: Epidemiologic characteristics and prognostic factors in 147 episodes. J Formas Med Assoc. 1999;98:465-473.
71. 71. Campagne G, Schuchat A, Djibo S, et al. Epidemiology of bacterial meningitis in Niamey, Niger, 1981-1996. Bull WHO. 1999;77:499-508.
72. 72. Ako-Nai AK, Adejuyigbe EA, Ajayi FM, Onipede AO. The bacteriology of neonatal septicaemia in Ile-Ife, Nigeria. J Trop Pediatr. 1999;45:146-151.
73. 73. Campagne G, Chippaux JP, Djibo S, et al. Epidemiology and control of bacterial meningitis in children less than 1 year in Niamey. Bull Soc Pathol Exot. 1999;92:118-122.
74. 74. Enarson DA, Chretien J. Epidemiology of respiratory infectious diseases. Curr Opin Pulm Med. 1999;5:128-135.
75. 75. Greenwood B. The epidemiology of pneumococcal infection in children in the developing world. Philos Trans R Soc Lond B Biol Sci. 1999;354:777-785.
76. 76. Rios AM, de la Hoz F, Leal AL, et al. The impact of antimicrobial resistance and Streptococcus pneumoniae serotype distribution on the mortality of children under 5 years of age with invasive disease. Rev Panam Salud Publica. 1999;5:69-76.
77. 77. Palmer A, Weber M, Bojang K, et al. Acute bacterial meningitis in The Gambia: A four-year review of pediatric hospital admissions. J Trop Pediatr. 1999;45:51-53.
78. 78. Davies HD, Schwartz B. Invasive group A streptococcal infections in children. Adv Pediatr Infect Dis. 1999;14:129-145.
79. 79. Reed MD, Goldfarb J, Blumer JL. Antiinfective therapy. In: Batimore RS, Jensen HB, eds. The Practice of Pediatric Infectious Diseases. Norwalk, Conn: Appleton & Lange. In press.
80. 80. Bradley JS. Selecting therapy for serious infections in children: Maximizing safety and efficacy. Diagn Microbiol Infect Dis. 1998;31:405-410.
81. 81. Durand ML, Calderwood SB, Weber DJ, et al. Acute bacterial meningitis in adults. A review of 493 episodes. N Engl J Med. 1993;328:21-28.
82. 82. Rasmussen BA, Bush K. Carbapenem-hydrolyzing β-lactamases. Antimicrob Agents Chemother. 1997;41:223-232.
83. 83. Sanders CC, Sanders WE Jr, Thomson KS, et al. Meropenem: Activity against resistant gram-negative bacteria and interactions with beta-lactamases. J Antimicrob Chemother. 1989;24(Suppl A): 187-196.
84. 84. Livermore DM. Determinants of the activity of beta-lactamase inhibitor combinations. J Antimicrob Chemother. 1993;31(Suppl A):9-21.
85. 85. American Hospital Formulary Service. Miscellaneous β-lactam antibiotics. In: AHFS Drug Information 98. Bethesda, Md: American Society of Health-System Pharmacists; 1998:206-240.
86. 86. Kohler J, Dorso KL, Young K, et al. In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum β-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolates. Antimicrob Agents Chemother. 1999;43:1170-1176.
87. 87. Hikida M, Itahashi K, Igarashi A, et al. In vitro antibacterial activity of LJC 11,036, an active metabolite of L-084, a new oral carbapenem antibiotic with potent antipneumococcal activity. Antimicrob Agents Chemother. 1999;43:2010-2016.
88. 88. Ohba F, Nakamur-Kamijo M, Watanabe N, Katsu K. In vitro and in vivo antibacterial activities of ER-35786, a new antipseudomonal carbapenem. Antimicrob Agents Chemother. 1997;41:298-307.
89. 89. Fukasawa M, Sumita Y, Harabe ET, et al. Stability of meropenem and effect of 1 beta-methyl substitution on its stability in the presence of renal dehydropeptidase 1. Antimicrob Agents Chemother. 1992;36:1577-1579.
90. 90. Wise R. In vitro and pharmacokinetic properties of the carbapenems. Antimicrob Agents Chemother. 1986;30:343-349.
91. 91. Tanio T, Nouda H, Tada E, et al. SM 7338, a new carbapenem antibiotic renal dehydropeptidase-1, stability and pharmacokinetics in animals. In: Proceedings and Abstracts of the Twenty-Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy. New York: 1987:229. Abstract. American Society for Microbiology, Washington, DC.
92. 92. Mollering RC, Eliopoulos GM, Sentochnik DE. The carbapenems: New broad spectrum β-lactam antibiotics. J Antimicrob Chemother. 1989;24(Suppl A): 1-7.
93. 93. Sunagawa M, Matsumura H, Inoue T, et al. A novel carbapenem antibiotic, SM-7338 structure-activity relationships. J Antibiotics. 1990;43:519-532.
94. 94. Sumita Y, Yamaga H, Sunagawa M. The effect of 1β-methyl substituent and the basicity in C-2 side chain in carbapenem antibiotics on the activity against Pseudomonas aeruginosa oprD2 and na1B mutants. J Antibiot (Tokyo). 1995;48:89-91.
95. 95. Sunagawa M, Matsumura H, Sasaki A, et al. Structure activity relationship of 1β-methyl-carbapenem to its antibacterial activity: Effect on of the C-2 side chain and the 1β-methyl group. J Antibiotics. 1996;49:1175-1178.
96. 96. Shibata K, Adachi Y, Kato E, et al. In vitro and in vivo evaluation of BO-2727 against imipenem-and/or meropenem-resistant Pseudomonas aeruginosa. J Antibiotics. 1997; 50:135-138.
97. 97. Labia R, Morand A, Guionic M. Beta-lactamase stability of imipenem. J Antimicrob Chemother. 1986;18(Suppl E):1-8.
98. 98. Christensen BG. Structure activity relationships in beta-lactam antibiotics. In: Salton MEJ, Schockman GD, eds. Beta-Lactam Antibiotics. Mode of Action, New Developments, and Future Prospects. London: Academic Press; 1981:101-125.
99. 99. Rosen H, Hajdu R, Silver L, et al. Reduced immunotoxicity and preservation of antibacterial activity in a releasable side-chain carbapenem antibiotic. Science. 1999;283: 703-706.
100. 100. Kanazawa K, Nouda H, Sumita Y, Sunagawa M. Structure-activity relationships of carbapenems to the antagonism of the antipseudomonal activity of other beta-lactam agents and to the beta-lactamase inducibility in Pseudomonas aeruginosa: Effects of 1 beta-methyl group and C-2 side chain. J Antibiot (Tokyo). 1999;52:142-149.
101. 101. Kanazawa K, Nouda H, Sunagawa M. Structure-activity relationships of carbapenem compounds to anti-Haemophilus influenzae. Activity and affinity for penicillin binding proteins, effect of 1 beta-methyl group and C-2 side chain. J Antibiotics. 1997;50:162-168.
102. 102. Sumita Y, Tada E, Nouda H, et al. Mode of action of meropenem, a new carbapenem antibiotic. Chemotherapy. 1992;40(Suppl 1):90-102.
103. 103. Sumita Y, Fukusawa M, Okuda T. Comparison of two carbapenems, SM-7338 and imipenem: Affinities for penicillin binding proteins and its release from these proteins and morphological changes. J Antibiotics. 1990;42:314-320.
104. 104. Kitzis MD, Acar JF, Gutmann L. Antibacterial activity of meropenem against gram-negative bacteria with a permeability defect and against staphylococci. J Antimicrob Chemother. 1989;24(Suppl A):125-132.
105. 105. Sato N, Ohba F. ER-35786. Carbapenem. Drugs Future. 1996;21:361-365.
106. 106. Jackson JJ, Kropp H. Differences in mode of action of β;-lactam antibiotics influence morphology, LPS release and in vivo antibiotic efficacy. J Endotoxin Res. 1996;3:201-208.
107. 107. Dofferhoff ASM, Nijland KH, de Vries-Hosper HG, et al. Effects of different types and combinations of antimicrobial agents on endotoxin release from gram-negative bacteria: An in vitro and in vivo study. Scand J Infect Dis. 1991;23:745-754.
108. 108. Horii T, Ichiyama S, Ohta M, Kobayashi M. Relationship between morphological changes and endotoxin release induced by carbapenems in Pseudomonas aeruginosa. J Med Microbiol. 1999;48:309-315.
109. 109. Mock CN, Jurkovich GJ, Dries DJ, Maier RV. Clinical significance of antibiotic endotoxin-releasing properties in trauma patients. Arch Surg. 1995;130:1234-1241.
110. 110. Cross AS, Opal SM. Endotoxin's role in gram-negative bacterial infection. Curr Opin Infect Dis. 1995;8:156-163.
111. 111. Van den Berg C, Neeling AJ, Schot CS, et al. Delayed antibiotic-induced lysis of Escherichia coli in vitro is correlated with enhancement of LPS release. Scand J Infect Dis. 1992;24:619-627.
112. 112. Shenep JL, Barton RP, Morgan KA. Role of antibiotic class in the rate of liberation of endotoxin during therapy for experimental gram-negative bacterial sepsis. J Infect Dis. 1985;151:1012-1018.
113. 113. Bodey GP, Bolivar R, Fainstein V, Jedeja L. Infections caused by Pseudomonas aeruginosa. Rev Infect Dis. 1984;5:279-313.
114. 114. Shenep JL, Flynn PM, Barret FF, et al. Serial quantitation of endotoxemia and bacteremia during therapy from gram-negative bacterial sepsis. J Infect Dis. 1988;157:565-568.
115. 115. Hurley JC, Louis WJ, Tosolini FA, Carlin JB. Antibiotic-induced release of endotoxin in chronically bacteriuric patients. Antimicrob Agents Chemother. 1991;35:2388-2394.
116. 116. Hurley JC. Antibiotic-induced release of endotoxin: A reappraisal. Clin Infect Dis. 1992; 15:840-854.
117. 117. Morrison DC, Bucklin SE. Evidence for antibiotic-mediated endotoxin release as a contributing factor to lethality in experimental gram-negative sepsis. Scand J Infect Dis. 1996;101(Suppl):3-8.
118. 118. Leibovici L, Drucker M, Konigsberger H, et al. Septic shock in bacteremic patients: Risk factors, features and prognosis. Scand J Infect Dis. 1997;29:71-75.
119. 119. Horii T, Kobayashi M, Sato K, et al. An in-vitro study of carbapenem-induced morphological changes and endotoxin release in clinical isolates of gram-negative bacilli. J Antimicrob Chemother. 1998;41:435-442.
120. 120. Prins JM, van Agtmael MA, Kuijper EJ, et al. Antibiotic-induced endotoxin release in patients with gram-negative urosepsis: A double-blind study comparing imipenem and ceftazidime. J Infect Dis. 1995;172:886-891.
121. 121. Arditi M, Ables L, Yogev R. Cerebrospinal fluid endotoxin levels in children with H. influenzae meningitis before and after administration of intravenous ceftriaxone. J Infect Dis. 1989;160:1005-1011.
122. 122. Jackson JJ, Kropp H. β-lactam antibiotic-induced release of free endotoxin: In vitro comparison of penicillin-binding (PBP) 2-specific imipenem and PBP 3-specific ceftazidime. J Infect Dis. 1992;165:1033-1041.
123. 123. Bucklin SE, Fujihara Y, Leeson MC, Morrison DC. Differential antibiotic-induced release of endotoxin from gram-negative bacteria. Eur J Clin Microbiol Infect Dis. 1994;13(Suppl 1):43-51.
124. 124. Trautmann M, Zick R, Rukavina T, et al. Antibiotic-induced release of endotoxin: In vitro comparison of meropenem and other antibiotics. J Antimicrob Chemother. 1998; 41:163-169.
125. 125. Trautmann M, Heinemann M, Zick R, et al. Antibacterial activity of meropenem against Pseudomonas aeruginosa, including antibiotic-induced morphological changes and endotoxin-liberating effects. Eur J din Microbiol Infect Dis. 1998;17:754-760.
126. 126. Woodford N, Palepou MFI, Babini GS, et al. Carbapenemase-producing Pseudomonas aeruginosa in UK. Lancet. 1998;352:546-547.
127. 127. Nakagawa S, Hashizume T, Matsuda K, et al. In vitro activity of a new carbapenem antibiotic, BO-2727, with potent antipseudomonal activity. Antimicrob Agents Chemother. 1993;37:2756-2759.
128. 128. Ubukata K, Hikida M, Yoshida M, et al. In vitro activity of LJ10,627, a new carbapenem antibiotic with high stability to dehydropeptidase 1. Antimicrob Agents Chemother. 1990;34:994-1000.
129. 129. Murray PR, Niles AC. In vitro activity of meropenem (SM-7338), imipenem and five other antibiotics against anaerobic clinical isolates. Diagn Microbiol Infect Dis. 1990;13:57-61.
130. 130. Edwards JR, Turner PJ, Wannop C, et al. In-vitro antimicrobial activity of SM-7338, a carbapenem antibiotic with stability to dehydropeptidase 1. Antimicrob Agents Chemother. 1989;33:215-222.
131. 131. Kayser FH, Morenzoni G, Starssle A, Hadorn K. Activity of meropenem against gram-positive bacteria. J Antimicrob Chemother. 1989;24(Suppl A):101-102.
132. 132. Phillips I, King A, Gransden WR, Eykyn SJ. The antibiotic sensitivity of bacteria isolated from blood of patients in St. Thomas' Hospital, 1969-1988. J Antimicrob Chemother. 1990;25(Suppl C):59-80.
133. 133. Ravizzola G, Pinsi G, Ginzales R, et al. Antibacterial activity of the new carbapenem meropenem (SM-7338) against clinical isolates. Eur J Clin Microbiol Infect Dis. 1989; 8:1053-1061.
134. 134. Nord CE, Lindmark A, Persson I. Susceptibility of anaerobic bacteria to meropenem. J Antimicrob Chemother. 1989;24(Suppl A): 113-117.
135. 135. Neu HC, Novelli A, Chin NX. In vitro activity and beta-lactamase stability of a new carbapenem SM-7338. Antimicrob Agents Chemother. 1989;36:1009-1018.
136. 136. Buckley MM, Brogden RN, Barradel ZB, Goa KL. Imipenem/cilastatin. A reappraisal of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1992;44:408-444.
137. 137. Fish DN, Singletary TJ. Meropenem, a new carbapenem antibiotic. Pharmacotherapy. 1997;17:644-669.
138. 138. Balfour JA, Bryson HM, Brogden RN. Imipenem/cilastatin. An update of this antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections. Drugs. 1996;51:99-136.
139. 139. Wiseman LR, Wagstaff AJ, Brogden RN, Bryson HM. Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs. 1995;50:73-101.
140. 140. Pryka RD, Haig GM. Meropenem: A new carbapenem antimicrobial. Ann Pharmacother. 1994;28:1045-1054.
141. 141. Craig WA. The pharmacology of meropenem, a new carbapenem antibiotic. Clin Infect Dis. 1997;24(Suppl 2):S266-S275.
142. 142. Clarke AM, Zemcov SJ. Comparative in vitro activity of biapenem, a new carbapenem antibiotic. Eur J Clin Microbiol Infect Dis. 1993;12:377-384.
143. 143. Hartenauer U, Weilemann LS, Bodmann KF, et al. Comparative clinical trial of ceftazidime and imipenem/cilastatin in patients with severe nosocomial pneumonias and septicaemias. J Hosp Infect. 1990;15(Suppl A):61-64.
144. 144. Calandra GB, Hesney M, Brown KR. Imipenem/cilastatin therapy of serious infections: A US multicenter noncomparative trial. Clin Ther. 1985;7:225-238.
145. 145. Ortqvist A, Kalin M, Julander I, Mufson MA. Deaths in bacteremic pneumococcal pneumonia. A comparison of two populations-Huntington, W Va, and Stockholm, Sweden. Chest. 1993;103:710-716.
146. 146. Hoge CW, Schwartz B, Talkington DF, et al. The changing epidemiology of invasive group A streptococcal infections and the emergence of streptococcal toxic shock-like syndrome. A retrospective population-based study. JAMA. 1993;269:384-389.
147. 147. Bonacorsi S, Fitoussi F, Lhopital S, Bingen E. Comparative in vitro activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime in combination with tobramycin, rifampin, or ciprofloxacin against Burkholderia cepacia isolates from patients with cystic fibrosis. Antimicrob Agents Chemother. 1999;43:213-217.
148. 148. Fitoussi F, Doit C, Benali K, et al. Comparative in vitro killing activities of meropenem, imipenem, ceftriaxone, and ceftriaxone plus vancomycin at clinically achievable cerebrospinal fluid concentrations against penicillin-resistant Streptococcus pneumoniae isolates from children with meningitis. Antimicrob Agents Chemother. 1998;42:942-944.
149. 149. Hudson VI, Weilinski CL, Regelmann WE. Prognostic implications of initial oropharyngeal bacterial flora in patients with cystic fibrosis diagnosed before the age of two years. J Pediatr. 1993;122:854-860.
150. 150. May TB, Shinabarger D, Maharaj R, et al. Alginate synthesis by Pseudomonas aeruginosa: A key pathogenic factor in chronic pulmonary infections of cystic fibrosis patients. Clin Microbiol Rev. 1991;4:191-206.
151. 151. Tablan OC, Chorba TL, Schidlow DV, et al. Pseudomonas cepacia colonization in patients with cystic fibrosis: Risk factors and clinical outcome. J Pediatr. 1985;107:382-387.
152. 152. Mathews A, Bailie GR. Clinical pharmacokinetics, toxicity and cost-effectiveness of aminoglycoside dosing services. J Clin Pharm Ther. 1987;12:273-291.
153. 153. Lacy MK, Lu W, Xu X, et al. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrob Agents Chemother. 1999;43:672-677.
154. 154. Ahonkhai VI, Cyhan GM, Wilson SE, Brown KR. Imipenem/cilastatin in pediatric patients: An overview of safety and efficacy in studies conducted in the U.S. Pediatr Infect Dis J. 1989;8:740-744.
155. 155. Overturf GD. Use of imipenem-cilastatin in pediatrics. Pediatr Inf Dis J. 1989;8:792-794.
156. 156. Bradley JS, Faulkner KL, Klugan KP. Efficacy, safety and tolerability of meropenem as empiric antibiotic therapy in hospitalized pediatric patients. Pediatr Inf Dis J. 1996;15: 749-757.
157. 157. Giamarellou H, Mandragos K, Bechrakis P, et al. Pefloxacin versus imipenem in the therapy of nosocomial lung infections of intensive care unit patients. J Antimicrob Chemother. 1990;26(Suppl B):117-127.
158. 158. Mouton Y, Deboscker Y, Bazin C, et al. A prospective, randomized, controlled trial of imipenem-cilastatin versus cefotaxime-amikacin in the treatment of lower respiratory tract infections and septicaemia in intensive care units. Presse Med. 1990;19:607-612.
159. 159. Lode H, Wiley R, Hoffken G, et al. Prospective randomised controlled study of ciprofloxacin versus imipenem-cilastatin in severe clinical infections. Antimicrob Agents Chemother. 1987;31:1491-1496.
160. 160. Kager L, Nord CE. Imipenem-cilastatin in the treatment of intraabdominal infections: A review of worldwide experience. Rev Infect Dis. 1985;7(Suppl 3):S518-S521.
161. 161. Sweet RL. Imipenem/cilastatin in the treatment of obstetric and gynecologic infections: A review of worldwide experience. Rev Infect Dis. 1985;7(Suppl 3):S522-S527.
162. 162. Brismar B, Akerlund JE, Sjostedt S, et al. Biapenem versus imipenem-cilastatin in the treatment of complicated intra-abdominal infections: Report from a Swedish study group. Scand J Infect Dis. 1996;28:507-512.
163. 163. Hara K, Hohno S, Koga H, et al. A comparative study of meropenem and imipenem/ cilastatin sodium in chronic respiratory tract infections. Chemotherapy (Tokyo). 1993; 40:1426-1450.
164. 164. Hara K, Sakamoto A, Komori K, et al. A comparative study of meropenem and imipenem/cilastatin sodium in bacterial pneumonia. Chemotherapy (Tokyo). 1992;40:1343-1364.
165. 165. Geroulanos SJ. Antibiotics and the abdomen. Curr Opin Infect Dis. 1994;(Suppl 1):S17-S22.
166. 166. Brismar B, Malmborg AS, Tunevall G, et al. Meropenem vs imipenem/cilastatin in the treatment of intraabdominal infections. J Antimicrob Chemother. 1995;35:139-148.
167. 167. Romanelli G, Cravarezza P, and Italian Intramuscular Meropenem Study Group. Intramuscular meropenem in the treatment of bacterial infections of urinary and lower respiratory tracts. J Antimicrob Chemother. 1995;36(Suppl A):109-119.
168. 168. Garau J, Blanquer J, Cobo L, et al. Prospective, randomised multicenter study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections. Eur J Clin Microbiol Infect Dis. 1997;16:789-796.
169. 169. Chang DC, Wilson SE. Meta-analysis of the clinical outcome of carbapenem monotherapy in the adjunctive treatment of intra-abdominal infections. Am J Surg. 1997; 174:284-290.
170. 170. Zanetti G, Harbarth SJ, Trampuz A, et al. Meropenem (1.5 g/day) is as effective as imipenem/cilastatin (2 g/day) for the treatment of moderately severe intra-abdominal infections. Int J Antimicrob Agents. 1999;11:107-113.
171. 171. Schlech WF III, Ward JI, Band JD, et al. Bacterial meningitis in the United States, 1978 through 1981. The National Bacterial Meningitis Surveillance Study. JAMA. 1985;253: 1749-1754.
172. 172. Laurichesse H, Grimaud O, Waight P, et al. Pneumococcal bacteraemia and meningitis in England and Wales, 1993 to 1995. Commun Dis Public Health. 1998;1:22-27.
173. 173. McGee ZA, Baringer JR. Acute meningitis. In: Mandell GL, Douglas RG, Bennett JE, eds. Principles and Practice of Infectious Diseases. 3rd ed. New York: Churchill Livingstone; 1990:741-755.
174. 174. Miller LG, Choi C. Meningitis in older patients: How to diagnose and treat a deadly infection. Geriatrics. 1997;52:43-44.
175. 175. Almirante B, Cortes E, Pigrau C, et al. Treatment and outcome of pneumococcal meningitis in adults. Study of a recent series of 70 episodes. Med Clin (Bare). 1995;105:681-686.
176. 176. Kirkpatrick B, Reeves DS, MacGowan AP. A review of the clinical presentation, laboratory features, antimicrobial therapy and outcome of 77 episodes of pneumococcal meningitis occurring in children and adults. J Infect. 1994;29:171-182.
177. 177. Klein JO, Feigin RD, McCracken GH. Report of the Task Force on Diagnosis and Management of Meningitis. Pediatrics. 1986;78:959-982.
178. 178. McCracken GH. Management of neonatal meningitis, 1984. J Antimicrob Chemother. 1984;14(Suppl B):23-31.
179. 179. Rosenstein NE, Perkins BA, Stephens DS, et al. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J Infect Dis. 1999;180:1894-1901.
180. 180. Feigin RD, Dodge PR. Bacterial meningitis: Newer concepts of pathophysiology and neurologic sequelae. Pediatr Clin North Am. 1976;23:541-556.
181. 181. Kaplan SL, Goddard J, Van Kleeck M, et al. Ataxia and deafness in children due to bacterial meningitis. Pediatrics. 1981;68:8-13.
182. 182. Modai J, Vittecoq D, Decazes JM, Meulemans A. Penetration of imipenem and cilastatin into cerebrospinal fluid of patients with bacterial meningitis. J Antimicrob Chemother. 1985;16:751-755.
183. 183. Saez-Llorens X, McCracken GH. Bacterial meningitis in neonates and children. Infect Dis Clin North Am. 1990;4:623-645.
184. 184. Syrogiannopoulos GA, Hansen EJ, Erwin AL, et al. Haemophilus influenzae type b lipooligosaccharide induces meningeal inflammation. J Infect Dis. 1988;157:237-244.
185. 185. Tauber MG, Shibl AM, Hackbarth CJ, et al. Antibiotic therapy, endotoxin concentration in cerebrospinal fluid, and brain edema in experimental Escherichia coli meningitis in rabbits. J Infect Dis. 1987; 156:456-462.
186. 186. Arditi M, Ables L, Yogev R. Kinetics of endotoxin in CSF of children with gram negative bacterial meningitis (Abstract No 6). Presented at 28th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 4-7, 1988; Los Angeles, Calif.
187. 187. Arditi M, Manogue KR, Yogev R. CSF cachectin activity in children with bacterial and aseptic meningitis. Pediatr Res. 1989;25:171A. Abstract.
188. 188. Mertsola J, Ramilo O, Mustafa MM, et al. Release of endotoxin after antibiotic treatment of gram-negative bacterial meningitis. Pediatr Infect Dis J. 1989;8:904-906.
189. 189. Wispelway B, Lesse AL, Hansen EJ, Scheid WM. Haemophilus influenzae type b lipopolysaccharide-induced blood-brain barrier permeability during experimental meningitis in the rat. J Clin Invest. 1988;82:1339-1346.
190. 190. McCracken GH. Current management of bacterial meningitis. Pediatr Infect Dis J. 1989;8:919-921.
191. 191. McCracken GH. Current management of bacterial meningitis in infants and children. Pediatr Infect Dis J. 1992;11:169-174.
192. 192. Mustafa MM, Mertsola J, Ramilo O, et al. Increased endotoxin and interleukin-1-beta concentrations in cerebrospinal fluid of infants with coliform meningitis and ventriculitis associated with intraventricular gentamicin therapy. J Infect Dis. 1989;160:891-895.
193. 193. Paris MM, Ramilo O, McCracken GH. Management of meningitis caused by penicillin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother. 1995;39:2171-2175.
194. 194. Catalan MJ, Fernandez MJ, Vazquez A, et al. Failure of cefotaxime in the treatment of meningitis due to relatively resistant Streptococcus pneumoniae. J Infect Dis. 1994; 18: 766-769.
195. 195. Saez-Llorens X, McCracken GH. Antimicrobial and anti-inflammatory treatment of bacterial meningitis. Infect Dis Clin North Am. 1999;13:619-637.
196. 196. Honorato J, Sadaba B, Diaz M. Clinical pharmacology and indications of meropenem in severe pediatric infection. Enferm Infecc Microbiol Clin. 1997;15(Suppl 1):38-44.
197. 197. Jacobs RF, Kearns EL, Brown AI, Longee DC. Cerebrospinal fluid penetration of imipenem and cilastatin (Primaxin) in children with central nervous system infections. Antimicrob Agents Chemother. 1986;29:670-674.
198. 198. Dagan R, Velghe L, Rodda JL, Klugman KP. Penetration of meropenem into the cerebrospinal fluid of patients with inflamed meninges. J Antimicrob Chemother. 1994;34: 175-179.
199. 199. Klugman KP, Dagan R. Carbapenem treatment of meningitis. Scand J Infect Dis. 1995;96:45-48.
200. 200. Van de Beek D, Hensen EF, Spanjaard L, et al. Meropenem susceptibility of Neisseria meninigitidis and Streptococcus pneumoniae from meningitis patients in The Netherlands. J Antimicrob Chemother. 1997;40:895-897.
201. 201. Hoiby N, Ciofu O, Jensen T, et al. Use of carbapenems and other antibiotics for pulmonary infections in patients with cystic fibrosis. Pediatr Infect Dis J. 1996;15:738-743.
202. 202. Pankuch GA, Hoellman DB, Jacobs MR, Appelbaum PC. Antipneumococcal activity of MEN 10700, a new penem, compared with other compounds, by MIC and time-kill kinetics. J Antimicrob Chemother. 1999;44:381-384.
203. 203. Ikemoto H, Ito C, Yoshida T, et al. Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (1997). Jpn J Antibiot. 1999;52: 353-397.
204. 204. Pedersen SS, Pressler T, Hoiby N, et al. Imipenem/cilastatin treatment of multiresistant Pseudomonas aeruginosa lung infection in cystic fibrosis. J Antimicrob Chemother. 1985;16:629-635.
205. 205. Webb AK. The treatment of pulmonary infection in cystic fibrosis. Scand J Infect Dis. 1995;96(Suppl):24-27.
206. 206. Byrne S, Maddison J, Connor P, et al. Clinical evaluation of meropenem versus ceftazidime for the treatment of Pseudomonas spp. infections in cystic fibrosis patients. J Antimicrob Chemother. 1995;36(Suppl A): 135-143.
207. 207. Kellner JD, Ford-Jones EL. Streptococcus pneumoniae carriage in children attending 59 Canadian childcare centers. Toronto Childcare Centre Study Group. Arch Pediatr Adolesc Med. 1999;153:495-502.
208. 208. Sala SK, Rikitomi N, Ruhulamin M, et al. Antimicrobial resistance and serotype distribution of Streptococcus pneumoniae strains causing childhood infections in Bangladesh, 1993-1997. J Clin Microbiol. 1999;37:798-800.
209. 209. Tauber MG, Zak O, Scheld WM, et al. The post-antibiotic effect in the treatment of experimental meningitis caused by Streptococcus pneumoniae in rabbits. J Infect Dis. 1984;149:575-583.
210. 210. Haruta T, Ohkura K, Kuroki S, et al. Studies on efficacy and safety of panipenem/ betamipron against infections in pediatrics and on its movement to cerebrospinal fluid including cases of penicillin-resistant Streptococcus pneumoniae meningitis. Jpn J Antibiot. 1992;45:416-423.
211. 211. Wong VK, Wright HT, Ross LA, et al. Imipenem/cilastatin treatment of bacterial meningitis in children. Pediatr Infect Dis J. 1991;10:122-126.
212. 212. Schmutzhard E, Williams KJ, Vukmirovits G, et al. A randomised comparison of meropenem with cefotaxime or ceftriaxone for the treatment of bacterial meningitis in adults. J Antimicrob Chemother. 1995;36(Suppl A):85-97.
213. 213. Esposito AL, Gleckman RA, Cram S, et al. Community-acquired bacteremia in the elderly: Analysis of one hundred consecutive episodes. J Am Geriatr Soc. 1980;28:315-319.
214. 214. McCue JD. Gram-negative bacillary bacteremia in the elderly: Incidence, ecology, etiology and mortality. J Am Geriatr Soc. 1987;35:213-218.
215. 215. Muder RR, Brennen C, Wagener MN, et al. Bacteremia in a long-term care facility: Five-year prospective study of 163 consecutive episodes. Clin Infect Dis. 1992;14:647-649.
216. 216. Meyers BR, Sherman E, Mendelson MH, et al. Bloodstream infections in the elderly. Am J Med. 1989;86:379-384.
217. 217. Grahn D, Norman DC, White ML, et al. Validity of urinary catheter specimen for diagnosis of urinary tract infections in the elderly. Arch Intern Med. 1985;145:1858.
218. 218. Gleckman RA. Urinary tract infection. Clin Geriatr Med. 1992;8:793-803.
219. 219. Warren JW. Catheter-associated bacteriuria. Clin Geriatr Med. 1992;8:805-819.
220. 220. Yoshikawa TT. Chronic urinary tract infections in the elderly patients. Hosp Pract. 1993;28:103-118.
221. 221. Starck H. Urinary tract infections in girls: The cost-effectiveness of currently recommended investigative routines. Pediatr Nephrol. 1997;11:174-177.
222. 222. Dick PT, Feldman W. Routine diagnostic imaging for childhood urinary tract infections: A systematic overview. J Pediatr. 1996;128:15-22.
223. 223. Honkinen O, Lhtonen O, Ruuskanen O, et al. Cohort study of bacterial species causing urinary tract infection and urinary tract abnormalities in children. Br Med J. 1999;318: 770-771.
224. 224. Rushton HG. Urinary tract infections in children. Epidemiology, evaluation, and management. Pediatr Clin North Am. 1997;44:1133-1169.
225. 225. Arrieta A. Use of meropenem in the treatment of serious infections in children: Review of the current literature. Clin Infect Dis. 1997;24(Suppl 2):S207-S212.
226. 226. Freij BJ, Kusmiesz H, Shelton S, et al. Imipenem and cilastatin in acute osteomyelitis and suppurative arthritis. Therapy in infants and children. Am J Dis Child. 1987;141: 335-342.
227. 227. Nishimura T, Sugita K, Aoki S, Takagi M. Bacteriological and clinical studies of biapenem (L-627) in the pediatric field. Jpn J Antibiot. 1994;47:940-949.
228. 228. Meguro H, Fujii R, Terashima 1, et al. Clinical evaluation of a new carbapenem antibiotic, biapenem (L-627), in the pediatric field. Jpn J Antibiot. 1994;47:903-913.
229. 229. Fujita K, Yoshikawa M, Murono K, et al. Clinical evaluation of biapenem (L627) in children. Jpn J Antibiot. 1994;47:873-877.
230. 230. Skiguchi T, Okamoto T, Ohara K, et al. Clinical studies on panipenem/betamipron in pediatrics. Jpn J Antibiot. 1992;45:430-436.
231. 231. Smith MD, Bielawska C, Kelsey MC, et al. Evaluation of imipenem/cilastatin for the treatment of infection in an elderly population. J Antimicrob Chemother. 1988;21:481-487.
232. 232. Cox CE, Corrado ML. Safety and efficacy of imipenem-cilastatin in treatment of complicated urinary tract infection. Am J Med. 1985;78(Suppl 6A):92-94.
233. 233. Cox CE, Holloway WJ, Geckler RW. A multicenter comparative study of meropenem and imipenem/cilastatin in the treatment of complicated urinary tract infections in hospitalized patients. Clin Infect Dis. 1995;21:86-92.
234. 234. Wood CA, Abrutyn E. Optimal treatment of urinary tract infections in elderly patients. Drugs Aging. 1996;9:352-362.
235. 235. Suseng MW, Ang P, Tan HH, Goh CL. Characteristics of bacterial skin infections in children compared to adults at a tertiary dermatologic center. Int J Dermatol. 1999;38: 582-586.
236. 236. Yoshida T, Homma K, Azami K, et al. Pharmacokinetics of meropenem in experimentally burned rats. J Dermatol. 1993;20:208-213.
237. 237. Wise R, Logan M, Cooper M, et al. Meropenem pharmacokinetics and penetration into inflammatory exudate. Antimicrob Agents Chemother. 1990;34:1515-1517.
238. 238. Nichols RL, Smith JW, Gecker RW, Wilson SE. Meropenem versus imipenem cilastatin in the treatment of hospitalized patients with skin and soft tissue infections. South Med J. 1995;88:397-404.
239. 239. Mouton JW, Michel MF. Pharmacokinetics of meropenem in serum and suction blister fluid during continuous and intermittent infusions. J Antimicrob Chemother. 1991;28: 911-918.
240. 240. Signs SA, Tan JS, Salstrom SJ, File TM. Pharmacokinetics of imipenem in serum and skin window fluid in healthy adults after intramuscular or intravenous administration. Antimicrob Agents Chemother. 1992;36:1400-1403.
241. 241. Arata J, Akiyama H, Kanzaki H, et al. A multicenter study on panipenem/betamipron in dermatology. Jpn J Antibiot. 1992;45:197-207.
242. 242. Condon RE, Walker AP, Hanna CB, et al. Penetration of meropenem in plasma and abdominal tissues from patients undergoing intraabdominal surgery. Clin Infect Dis. 1997;24(Suppl 2):S181-S183.
243. 243. Fass RJ, Freimer EH, McCloskey RV. Treatment of skin and soft tissue infections with imipenem/cilastatin. Am J Med. 1985;78:110-112.
244. 244. Pitkin D, Sheikh W, Wilson S, et al. Comparison of the activity of meropenem with that of other agents in the treatment of intraabdominal, obstetric/gynecologic, and skin and soft tissue. Clin Infect Dis. 1995;20(Suppl 2):S372-S375.
245. 245. Lami JL, Wilson SE, Hopkins JA. Adjunctive antimicrobials in surgery of soft tissue infections: Evaluation of cephalosporins and carbapenems. Am Surg. 1991;57:769-774.
246. 246. Garau J, Calandra GB. Intramuscular imipenem/cilastatin in multiple-dose treatment regimens: Review of the worldwide clinical experience. Chemotherapy. 1991;37(Suppl 2):44-52.
247. 247. Sexton DJ, Wlodaver CG, Tobey LE, et al. Twice daily intramuscular imipenem/ cilastatin in the treatment of skin and soft tissue infections. Chemotherapy. 1991; 37(Suppl 2):26-30.
248. 248. Gould IM, Hudson M, Morris J, et al. Imipenem versus standard therapy in the treatment of serious soft tissue infection. Drugs Exp Clin Res. 1988;14:555-558.
249. 249. Calandra GB, Raupp W, Brown KR. Imipenem/cilastatin treatment of lower extremity skin and soft tissue infections in diabetics. Scand J Infect Dis Suppl. 1987;52:15-19.
250. 250. Marier RL. Role of imipenem/cilastatin in the treatment of soft tissue infections. Am J Med. 1985;78:140-144.
251. 251. Gray JW, Pedler SJ, Craft AW, et al. Changing causes of septicaemia in pediatric oncology patients: Effect of imipenem use. Eur J Pediatr. 1994;153:84-89.
252. 252. Kremery V, Trup J, Kunova A, et al. Imipenem-resistant Ps. aeruginosa bacteremia in cancer patients: Risk factors, clinical features and outcome. Int J Clin Pharmacol Res. 1996;16:43-49.
253. 253. Del Valle J, Noriega AR, Sanz F, et al. Efficacy and safety of imipenem-cilastatin in the empirical treatment of septicemia. Scand J Infect Dis Suppl. 1987;52:20-25.
254. 254. Eron LJ. Imipenem-cilastatin therapy of bacteremia. Am J Med. 1985;78:95-99.
255. 255. Solberg CO, Sjursen H. Safety and efficacy of meropenem in patients with septicaemia: A randomised comparison with ceftazidime, alone or combined with amikacin. J Antimicrob Chemother. 1995;36(Suppl A): 157-166.
256. 256. Bohme A, Just-Nubling G, Bergmann L, et al. A randomized study of imipenem compared to cefotaxime plus piperacillin as initial therapy of infections in granulocytopenic patients. Infection. 1995;23:349-355.
257. 257. Schuler D. Safety and efficacy of meropenem in hospitalised children: Randomised comparison with cefotaxime, alone and combined with metronidazole or amikacin. Meropenem Paediatric Study Group. J Antimicrob Chemother. 1995;36(Suppl A):99-108.
258. 258. Principi N, Marchisio P. Meropenem compared with ceftazidime in the empiric treatment of acute severe infections in hospitalized children. Italian Pediatric Meropenem Study Group. J Chemother. 1998;10:108-113.
259. 259. Behre G, Link H, Maschmeyer G, et al. Meropenem monotherapy versus combination therapy with ceftazidime and amikacin for empirical treatment of febrile neutropenic patients. Ann Hematol. 1998;76:73-80.
260. 260. Cometta A, Baumgartner JD, Lew D, et al. Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for the treatment of severe infections in nonneutropenic patients. Antimicrob Agents Chemother. 1994;38:1309-1313.
261. 261. Mouton YJ, Beutcart C, and the Meropenem Study Group. Empirical monotherapy with meropenem in serious bacterial infections. J Antimicrob Chemother. 1995;36(Suppl A): 145-156.
262. 262. Raad II, Abi-said D, Rolston KV, et al. How should imipenem-cilastatin be used in the treatment of fever and infection in neutropenic cancer patients? Cancer. 1998;82:2449-2458.
263. 263. Winston DJ, Ho WG, Bruchner DA, et al. Beta-lactam antibiotic therapy in febrile granulocytopenic patients: A randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone. Ann Intern Med. 1991;115:849-859.
264. 264. Calandra G, Lydick E, Carrigan J, et al. Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: Experience with imipenem/cilastatin. Am J Med. 1988:84:911-918.
265. 265. Data on file. ER35786-RIB. Tokyo, Japan: Eisai Co. Ltd; 1997.
266. 266. De Turck BJ, Diltoer MW, Cornelis PJ, et al. Lowering of plasma valproic acid concentrations during concomitant therapy with meropenem and amikacin. J Antimicrob Chemother. 1998;42:563-564.
267. 267. Yamagata T, Momoi MY, Murai K, et al. Panipenem-betamipron and decreases in serum valproic acid concentration. Ther Drug Monit. 1998;20:396-400.
268. 268. Nagai K, Shimizu T, Togo A, et al. Decreases in serum levels of valproic acid during treatment with a new carbapenem, panipenem/betamipron. J Antimicrob Chemother. 1997;39:295-296.
269. 269. Bax RP, Bastain W, Featherstone A, et al. The pharmacokinetics of meropenem in volunteers. J Antimicrob Chemother. 1989;24(Suppl A):311-320.
270. 270. Umemura K, Ikeda Y, Kondo K, et al. Safety and pharmacokinetics of CS-834, a new oral carbapenem antibiotic, in healthy volunteers. Antimicrob Agents Chemother. 1997; 41:2664-2669.
271. 271. Drusano GL, Standiford HC. Pharmacokinetic profile of imipenem/cilastatin in normal volunteers. Am J Med. 1985;78:47-53.
272. 272. Norrby SR, Bjornegard B, Ferber F, Jones KH. Pharmacokinetics of imipenem in healthy volunteers. J Antimicrob Chemother. 1983;12(Suppl D):109-124.
273. 273. Norrby SR, Alestig K, Ferber F, et al. Pharmacokinetics and tolerance of N-formimidoyl thienamycin (MK0787) in humans. Antimicrob Agents Chemother. 1983;23:293-299.
274. 274. Kim SH, Kim WB, Lee MG. No effect of probenecid on the renal excretion mechanism of a new carbapenem, DA-1131, in dogs. Res Commun Mol Pathol Pharmacol. 1998;101: 85-92.
275. 275. Kim SH, Kim WB, Lee MG. Effect of probenecid on the renal excretion mechanism of a new carbapenem, DA-1131, in rats and rabbits. Antimicrob Agents Chemother. 1999;43: 96-99.
276. 276. Matsumoto T, Kumazawa J, Nagayama A. Sensitivities to four carbapenems of bacteria isolated from patients with refractory complicated urinary tract infections and the detection of carbapenemase-producing Pseudomonas aeruginosa. J Antimicrob Chemother. 1996;38:322-324.
277. 277. Livermore DM. Carbapenemases. J Antimicrob Chemother. 1992;29:609-613.
278. 278. Livermore DM. Carbapenemases: The next generation of β-lactamases? ASM News. 1993;59:129-135.
279. 279. Payne DJ. Metallo-β-lactamases-a new therapeutic challenge. J Med Microbiol. 1993; 39:93-99.
280. 280. Bandoh KK, Ueno K, Watanabe K, Kato N. Susceptibility patterns and resistance to imipenem in the Bacteroides fragilis group species in Japan: A 4-year study. Clin Infect Dis. 1993;16(Suppl 4):S382-S386.
281. 281. Minami S, Akama M, Araki H, et al. Imipenem and cephem resistant Pseudomonas aeruginosa carrying coding for class B β-lactamase. J Antimicrob Chemother. 1996;37: 433-444.
282. 282. Senda K, Arakawa Y, Nakashima K, et al. Multifocal outbreaks of metallo-β-lactamase producing Pseudomonas aeruginosa resistant to broad-spectrum β-lactams, including carbapenems. Antimicrob Agents Chemother. 1996;40:349-353.
283. 283. Segarra-Newnham M. Use of large-dose gentamicin regimens in elderly men. Hosp Pharm. 1999;34:420-422.
284. 284. Marra F, Reynolds R, Stiver G, et al. Piperacillin/tazobactam versus imipenem: A double-blind, randomized formulary feasibility study at a major teaching hospital. Diagn Microbiol Infect Dis. 1998;31:355-368.
285. 285. Castagnola E, Paola D, Giacchino R, et al. Economic aspects of empiric therapy for febrile neutropenia in children with cancer. Supportive Care Cancer. 1998;6:524-528.
286. 286. Au E, Tow A, Alien DM, Ang PT. Randomised study comparing imipenem/cilastatin to ceftriaxone plus gentamicin in cancer chemotherapy-induced neutropenic fever. Ann Acad Med Singapore. 1994;23:819-822.
287. 287. Jhee SS, Gill MA, Yellin AE, et al. Pharmacoeconomics of piperacillin/tazobactam and imipenem/cilastatin in the treatment of patients with intraabdominal infections. Clin Ther. 1995;17:126-135.
288. 288. Keter B. Cost-analysis of imipenem-cilastatin monotherapy compared with clindamycin + aminoglycoside combination therapy for the treatment of serious lower respiratory, intraabdominal, gynecologic and urinary tract infections. Clin Ther. 1992;14:110-121.
289. 289. Rodloff AC, Kujath P, Lunstedt B, Gaus W. Comparative study of the cost-effectiveness of initial therapy with imipenem/cilastatin in secondary peritonitis. Chirurg. 1998;69: 1093-1100.
290. 290. Norrby SR, Eriksson M, Ottosson E. Imipenem/cilastatin versus gentamicin/clindamycin: A cost-effectiveness study. Scand J Infect Dis. 1986;18:371-374.
291. 291. Rodloff AC, Laubenthal HJ, Bastian A, et al. Comparative study of the cost-effectiveness relationship of initial therapy with imipenem/cilastatin in nosocomial pneumonia. Group study. Anasthesiol Intensivmed Notfallmed Schmerzther. 1996;31:172-180.